Revance Therapeutics (RVNC) Reports In-Line Q4 EPS, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Revance Reports Fourth Quarter and Full Year 2020 Financial Results
February 22, 2021 4:05 PM ESTFourth quarter and full year 2020 total product and service revenue of $10.2 million and $13.3 million, respectively First full quarter of RHA® Collection of dermal fillers revenue of $10.0 million Exited 2020 with over $200 million in annualized HintMD processing volume Cash, cash equivalents and short-term investments balance of $436.5 million at year-end, with cash into 2024 Today announced positive data from JUNIPER Phase 2 Trial of DaxibotulinumtoxinA for Injection for adult upper limb spasticity Conference call and webcast today at 4:30 p.m. ET
NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics,... More
